Eli Lilly stock steadies near record territory as obesity and diabetes drugs power double digit growth

Eli Lilly & Co. (ISIN US5324571083) stock has been trading near record territory in recent weeks as investors focus on the United States pharma groups rapid expansion in obesity and diabetes medicines, underpinned by double digit top line and earnings growth in 2024 according to company and market data from early July 2024.

Revenue up over 30 percent on blockbuster drugs

According to Eli Lillys quarterly filings for Q1 2024, the group generated revenue of approximately $8.77 billion in the first quarter of 2024, an increase of around 26 percent compared with roughly $6.96 billion in the same period of 2023, driven largely by its incretin based diabetes and obesity portfolio and other key medicines.

The company reported that its flagship GLP 1 based medicine for type 2 diabetes and obesity delivered a multi billion dollar contribution to sales in Q1 2024, with revenue rising strongly versus the prior year period as more patients initiated therapy and as the drug became available in additional markets beyond the United States.

Net income and EPS accelerate alongside sales growth

In the same Q1 2024 report, Eli Lilly indicated that its reported net income rose to roughly $2.24 billion, compared with about $1.34 billion in Q1 2023, reflecting both the higher sales base and improved operating leverage as fixed costs were spread across a larger revenue pool.

Diluted earnings per share for Q1 2024 were reported at around $2.62, up from approximately $1.49 in the first quarter of 2023, meaning EPS increased by close to 76 percent year on year as the impact of higher product demand and a richer mix in favor of newer, higher margin therapies flowed through the income statement.

GLP 1 demand reshapes portfolio mix

Eli Lilly has highlighted in its recent presentations that its metabolic and obesity treatments have rapidly become a central growth engine, with management pointing out that incretin therapies now account for a significantly larger share of group revenue than a few years ago as patient demand accelerates in the United States and internationally.

The company has invested heavily in manufacturing capacity expansions for its incretin portfolio, indicating in 2024 updates that several new production facilities are under construction or ramping up, with multi billion dollar capital expenditure earmarked between 2023 and 2026 to reduce supply constraints and support further volume growth.

Pipeline, R and D and capital allocation

Besides obesity and diabetes, Eli Lilly continues to allocate a substantial proportion of revenue to research and development, with R and D expenses running at several billion dollars annually in recent years as the group advances programs in oncology, immunology, neuroscience and other therapeutic areas.

The company has also maintained a regular dividend track record and has historically executed share repurchases when management judged the capital allocation to be attractive, although the growing scale of investment needs for manufacturing and pipeline development has increased the relative importance of reinvestment in the business.

Obesity treatment as key product line

Eli Lillys incretin based obesity treatment has become one of the most closely watched products in the global pharmaceutical market, with analysts estimating that annualized sales already run at several billion dollars and could grow further as new indications and geographies are added over the next few years.

The treatment is part of a broader push in cardiometabolic health, where the company is exploring additional uses that could expand the addressable market and deepen its competitive moat against rival therapies.

Eli Lilly stock and market valuation

Eli Lilly stock is listed on the New York Stock Exchange in US dollars, and the companys market capitalization has climbed into the upper hundreds of billions of dollars in 2024 as investors price in sustained high growth from its obesity and diabetes franchises alongside contributions from other therapeutic areas.

At recent prices in early July 2024, the shares traded at a forward earnings multiple that reflects strong growth expectations compared with the broader S and P 500 health care sector, indicating that the market is already assigning a premium valuation to the companys pipeline and commercial execution.